Savolitinib-Osimertinib Combo Achieves 8.2 vs 4.5-Month PFS, Wins China Approval
AstraZeneca's savolitinib plus osimertinib combination demonstrated an investigator-assessed median PFS of 8.2 vs 4.5 months (HR 0.34; p<0.0001) in EGFR-mutated NSCLC with MET amplification. China granted approval for the regimen in June 2025 following positive interim data, with full results published in The Lancet.
Related News
ING
ING-backed euro stablecoin consortium grows to 37 banks, eyes H2 launch
ING•
EXR
Extra Space Storage Adds Retail and Tech Executives with 850-Unit Chain, Ex-Matterport CEO to Board
EXR•
GOOG
OpenAI Eyes Fall IPO After Lawsuit Win, Battling $900B Anthropic Rival
GOOG•
NVDA
Hedge Funds Back Nvidia-Powered AI Data Centers as Shares Fall 1.3% After $80B Buyback
NVDA•
MA
Chargebacks911 Partners with acceptcards to Reduce Chargebacks as UK Card Use Tops £1 Trn
MA•
Sources
ZGRGG